-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Nabriva Therapeutics plc quarterly/annual Operating Income (Loss) history and growth rate from 2014 to 2022.
- Nabriva Therapeutics plc Operating Income (Loss) for the quarter ending June 30, 2023 was -$12M, a 15.6% decline year-over-year.
- Nabriva Therapeutics plc Operating Income (Loss) for the twelve months ending June 30, 2023 was -$54M, a 18.3% decline year-over-year.
- Nabriva Therapeutics plc annual Operating Income (Loss) for 2022 was -$55.5M, a 14.3% decline from 2021.
- Nabriva Therapeutics plc annual Operating Income (Loss) for 2021 was -$48.5M, a 26.6% increase from 2020.
- Nabriva Therapeutics plc annual Operating Income (Loss) for 2020 was -$66.1M, a 16.8% increase from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)